Teva
Last updated Jun 21, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
81%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Neurology
- Multiple System Atrophy
- Dermatology
- Vitiligo
Highest priority development: FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Regulatory precedent
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Teva.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 81%
Active Signals
2
Investigate Priority
0
Opportunity Score
44
Buyer Quality
4 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 21, 2026Score 22Teva's TEV-56286 Trial for Multiple System Atrophy Underway
Neurology · Multiple System Atrophy
- MonitorJun 19, 2026Score 22Teva's TEV-53408 Trial for Vitiligo Focuses on Safety and Efficacy
Dermatology · Vitiligo
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Teva right now?
- Which regulatory precedents should Teva monitor in Neurology and Multiple System Atrophy?
- How does Pridopidine Phase 3 Trial compare to the nearest competitive programs?
- What signals require immediate investigation for Teva?
- Summarize the strategic implications of recent developments for Teva.
- Where is the greatest uncertainty in Teva's competitive positioning?